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Abstract 
Background: Increasing evidence suggest that statin therapy has a diabetogenic effect. Individual types of statin 
may have a different effect on glucose metabolism. Using the repeated nationwide population‑based health screen‑
ing data in Korea, we investigated the longitudinal changes in fasting glucose level of non‑diabetic individuals by use 
of statins.
Methods: From the National Health Screening Cohort, we included 379,865 non‑diabetic individuals who had ≥ 2 
health screening examinations with fasting blood glucose level measured in 2002–2013. Using the prescription 
records of statins in the database, we calculated the proportion of days covered (PDC) and average number of 
defined daily doses per day (anDDD) by statins. We constructed multivariate linear mixed models to evaluate the 
effects of statins on the changes in fasting glucose (Δglu).
Results: High PDC by statins had a significant positive effect on Δglu (coefficient for PDC 0.093 mmol/L, standard 
error 0.007, p < 0.001). anDDD by statins was also positively associated with Δglu (coefficient for anDDD 0.119 mmol/L, 
standard error 0.009, p < 0.001). Unlike statins, the PDC by fibrate and ezetimibe were not significantly associated with 
Δglu. There was no significant interaction effect on Δglu between time interval and statin. Considering individual 
types of statins, use of atorvastatin, rosuvastatin, pitavastatin, and simvastatin were significantly associated with 
increase of Δglu. Pravastatin, lovastatin, and fluvastatin were also positively associated with Δglu, but were not statisti‑
cally significant.
Conclusions: More adherent and intensive use of statins was significantly associated with an increase in fasting glu‑
cose of non‑diabetic individuals. In subgroup analysis of individual statins, use of atorvastatin, rosuvastatin, pitavasta‑
tin and simvastatin had significant association with increase in fasting glucose. Pravastatin, lovastatin, and fluvastatin 
had non‑significant trend toward an increased fasting glucose. Our findings suggest the medication class effect of 
statins inducing hyperglycemia.
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Background
Statins, 3-hydroxy-3-methylglutaryl-coenzyme reductase 
(HMGCR) inhibitors, are class of lipid lowering medi-
cations with pleiotropic properties due to anti-inflam-
matory, anti-thrombotic, and anti-oxidative effects [1]. 
It is well-established that statins can reduce the risk for 
cardiovascular and cerebrovascular diseases [2]. In clini-
cal practice, statins have a major role in the prevention 
of cardiovascular disease for those at higher risk. Besides 
the cardiovascular benefits, there are concerns that 
statins may lead to hyperglycemia and increase the risk of 
new-onset diabetes mellitus (DM) [3–5]. In randomized 
and observational studies, there was a higher incidence 
of new-onset DM in patients receiving statin compared 
to those who were not [4]. As DM is a major risk factor 
of cardiovascular disease and various long-term compli-
cations, this is a clinically important issue. But also DM, 
impaired fasting glucose and pre-diabetes are significant 
cardiovascular risk factor [6–8]. Experimental and clini-
cal data suggested that statins may lead to the increase 
of insulin-resistance and hyperglycemia [9, 10]. How-
ever, there are still insufficient data for the longitudinal 
changes in fasting glucose with the use of statins. In addi-
tion, there are multiple types of statin, each with a differ-
ent chemical structure and pharmacokinetic profile [11, 
12]. The individual statin types may have different effects 
on glucose metabolism [13, 14]. To investigate these 
issues, we conducted a longitudinal study to analyze the 
changes in fasting glucose by use of statins based on data 
from repeatedly performed nationwide health examina-
tions in Korea.
Methods
Data source
This study was based on the National Health Insur-
ance Service-National Health Screening Cohort (NHIS-
HEALS) in Korea [15]. The NHIS offers a free health 
examination program to all members ≥ 40 years old every 
2  years. Among the Korean subjects aged 40–79 who 
underwent the health examination during 2002–2003, 
about 10% (n = 541,866) were randomly selected to form 
the NHIS-HEALS. NHIS-HEALS contained serial health 
examination data including fasting glucose, blood pres-
sure, body mass index (BMI), questionnaire for lifestyle, 
and every individual’s health insurance claim data for 
hospital visits, medical procedures, diagnoses (based on 
International Statistical Classification of Diseases and 
Related Health Problems 10th Revision, ICD-10), and 
drug prescriptions during the study period of 2002–2013. 
All included subjects were followed-up until death, loss 
of eligibility for NHIS due to emigration, or Dec 31, 2013, 
which is the end of the study period.
Study subjects
To investigate the longitudinal change in fasting glu-
cose, we selected subjects who had data on their fasting 
glucose level from at least 2 health examinations dur-
ing the study period of 2002–2013. For each subject, 
the baseline value of fasting glucose was defined as the 
value at the first health examination. As the use of anti-
diabetic medication can influence the fasting glucose 
level, we only included non-diabetic individuals. There-
fore, we excluded patients who (1) had a fasting glucose 
level ≥ 7 mmol/L at the baseline health examination, (2) 
answered “yes” to the diagnosis of DM on the question-
naire in health examination, (3) had a diagnosis of DM 
(ICD-10 code ‘E10–E15’) from the health insurance claim 
data, and (4) had received a prescription for anti-diabetic 
medication during the study period.
Data collection
In the serial NHIS health examinations, data were col-
lected for sex, age, BMI, household income, and systolic 
blood pressure. At each examination, fasting glucose was 
measured with a venous blood sample after more than 
6 h of fasting. The questionnaire for lifestyle in the health 
examination contained questions regarding smoking sta-
tus, alcohol consumption, and physical activity [15]. Alco-
hol consumption was classified into ‘less than 1 time’, ‘1–2 
times’, ‘3–4 times’, and ‘≥ 5 times’ according to the how 
many times alcohol was consumed per week on average. 
Physical activity was grouped into ‘< 1 day’, ‘1–4 days’, and 
‘≥ 5 days’ according to the number of days of exercise per 
week on average (regardless of type or duration of exer-
cise). Health examination data with missing values for any 
of fasting glucose or covariates (sex, age, BMI, household 
income, systolic blood pressure, smoking status, alco-
hol consumption, and physical activity) were excluded 
from the analysis. Health examination data with extreme 
values of fasting glucose (≤ 3 or ≥ 25 mmol/L) were also 
excluded [16]. If the initial health examination data in 
each patient was excluded due to incomplete data for fast-
ing glucose or covariates, the next health examination was 
treated as baseline data for the patient.
Statistical analysis with data for medications
As fasting glucose was measured repeatedly, we con-
structed a linear mixed-effect model to analyze the 
change in fasting glucose (Δglu = gluexam − glubase, 
mmol/L) over time. In the linear mixed-effect model, 
variables of fixed effects were sex, age, fasting glucose 
level at baseline (initial measurement), time interval 
(Δtime; time between baseline and serial measurements), 
use of statins during the time interval, and other clini-
cal characteristics obtained from the serial NHIS health 
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examinations (systolic blood pressure, BMI, household 
income, smoking status, alcohol consumption, and physi-
cal activity). The general structure for the mixed model 
was Δglu = β*time + β*statin + β*other covariates + inter-
cept (where β is a regression coefficient for the variable). 
To evaluate the effect of statins on the change in fast-
ing glucose, we calculated the β of statins in the linear 
mixed model. As markers of statin use during the period 
between baseline and serial measurements, we calcu-
lated 1) proportion of days covered (PDC) = ‘number of 
days covered by statins divided by total number of days’ 
and 2) average number of defined daily doses per day 
(anDDD) = ‘cumulative doses of statins during the period 
divided by total number of days and defined daily dose 
of each statin’. Defined daily doses (DDD) of each sta-
tin were 20 mg for atorvastatin, 10 mg for rosuvastatin, 
2  mg for pitavastatin, 30  mg for pravastatin, 30  mg for 
simvastatin, 45  mg for lovastatin, and 60  mg for fluvas-
tatin according to the World Health Organization. If a 
subject received 40 mg of atorvastatin for 180 days dur-
ing a period of 760  days between the baseline and next 
NHIS health examination, PDC by statins over the period 
would be 180/760 = 0.25 and anDDD by statins would be 
40*180/20/760 = 0.5. If a subject received 20 mg of ator-
vastatin for 60 days followed by 10 mg of rosuvastatin for 
120 days during a period of 360 days between the base-
line and next NHIS health examination, PDC by statins 
would be (60 + 120)/360 = 0.5 (PDC by atorvastatin 
would be 0.166 and PDC by rosuvastatin would be 0.333) 
and anDDD by statins would be (20*60/20 + 10*120/10)
/360 = 0.570. In this case, anDDD by atorvastatin would 
be 20*60/20/360 = 0.237 and anDDD by rosuvastatin 
would be 10*120/10/360 = 0.333. To evaluate the effects 
of non-statin lipid-lowering medications on glucose, we 
also calculated data of PDC by fibrate (bezafibrate, cip-
rofibrate, etofibrate, fenofibrate, and gemfibrozil) and 
ezetimibe during the study period in the same manner. 
The data management and statistical analyses were per-
formed with the SAS statistical software package, version 
9.4 (SAS Institute Inc., Cary, NC, USA) and R software, 
version 3.4.3 (The R Foundation for Statistical Comput-
ing, Vienna, Austria; http://www.R-proje ct.org/). A two-
sided p < 0.05 was regarded as statistically significant.
Results
Subjects
According to the inclusion and exclusion criteria, we 
finally included 379,865 non-diabetic subjects who 
received ≥ 2 measurements of fasting glucose level 
(Fig.  1). The mean age at the baseline NHIS health 
NHIS–HEALS
N=514,866
2,779,959 times of health 
examination
N=512,322
2,656,308 times of health 
examination 
Exclusion of 22,648 patients due to only 1 time heath
examination with available data
N=402,513
2,140,246 times of health 
examination
N=379,865
2,117,598 times of health 
examination with fasting glucose 
level
Exclusion of 123,651 times of health examination
1) Missing or extreme value of glucose 
 3 mmol/L or  25 mmol/L)
2) missing value for other collected variables
Exclusion of 109,809 patients*
1) diagnosis of diabetes mellitus
2) fasting glucose  7 mmol/L
3) exposure to anti-diabetic medication
Fig. 1 Flow chart of patients according to inclusion and exclusion criteria. NHIS‑HEALS, the National Health Insurance Service‑National Health 
Screening Cohort in Korea. *Those who met the exclusion criteria in any time of study period were excluded
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examination was 51.9 ± 9.2  years and males comprised 
52.6% of the subjects. During the study period, the 
median number of glucose measurements per subject 
was 5 (interquartile range, 4–6). The clinical characteris-
tics of the included subjects are summarized in Table 1. 
Among the included subjects, the prevalence of exposure 
to statins (at least 1 prescription of statins during the 
study period) was 25.3% (Table 2). The total cumulative 
duration of exposure to any statins were 165,083  years. 
The proportion of patients who were exposed to fibrate 
and ezetimibe were 3.9% and 1.5%, respectively.
Factors associated with the change in fasting glucose
In the multivariate linear mixed model for the change 
in fasting glucose (Δglu), being male, older age, lower 
fasting glucose level at baseline, higher systolic blood 
pressure, higher BMI, being a current smoker, lower 
household income, higher alcohol consumption, and less 
exercise were positively associated with Δglu (Table  3). 
High PDC by statins had a significant positive effect on 
Δglu (coefficient for PDC 0.093 mmol/L, standard error 0.007, p < 0.001), which indicates that adherent use of 
statins was associated with an increase in fasting glu-
cose. Unlike statins, PDC by fibrate (coefficient for PDC 
0.022  mmol/L, standard error 0.025, p = 0.387) and 
ezetimibe (coefficient for PDC 0.046  mmol/L, stand-
ard error 0.045, p = 0.314) were not significantly associ-
ated with Δglu. When we performed analysis including 
anDDD in place of PDC as a marker of statin intensity, 
anDDD by statins was also positively associated with 
Δglu (coefficient for anDDD 0.119  mmol/L, standard 
error 0.009, p < 0.001). These findings suggested that 
more adherent and intensive statin therapy could cause 
an increase in fasting glucose. We plotted the estimated 
change in Δglu according to statin therapy in the linear 
mixed models including the interaction term between 
time and statin therapy (Fig.  2). In the plots, Δglu 
increased in proportion to PDC and anDDD without 
the lines crossing over time indicating that there was 
no interaction effect between time interval and statin 
therapy.
Effect of each statin type on the change in fasting glucose
To investigate the effect of each statin type on fasting glu-
cose, we reconstructed the linear mixed model to include 
PDC for each type of statin. Figure 3 shows the coefficient 
of PDC for each statin for Δglu. PDC of atorvastatin, 
rosuvastatin, pitavastatin, and simvastatin had significant 
positive effects on Δglu. PDC of pravastatin, lovastatin, 
and fluvastatin also had positive effects on Δglu, but were 
not statistically significant. When we included anDDD 
of each statin instead of PDC, there was a similar find-
ing; anDDD by atorvastatin, rosuvastatin, pitavastatin, 
and simvastatin had significant positive effects on Δglu, 
Table 1 Characteristics of the included subjects
Data are represented as number (%), mean ± standard deviation, or median 
[interquartile range]
Variable Value
Number of subjects 379,865
Total number of health examinations 2,117,598
 Number of health examination per subject 5 [4–6]
 Time period between baseline to last health examina‑
tion per subject (years)
8.96 ± 2.12
Variables at baseline health examination
 Sex (male) 199,786 (52.6)
 Age (years) 51.91 ± 9.19
 Fasting glucose (mmol/L) 5.02 ± 0.68
 Systolic blood pressure, mmHg 125.38 ± 17.55
 Body mass index (kg/m2) 23.79 ± 2.87
 Current smoker 33,840 (8.9)
Alcohol consumption, frequency per week (times)
 < 1 215,773 (56.8)
 1–2 123,573 (32.5)
 3–4 25,446 (6.7)
 ≥ 5 15,073 (4.0)
Exercise, days per week (days)
 < 1 215,736 (56.8)
 1–4 129,356 (34.1)
 ≥ 5 34,773 (9.2)
Household income
 Q1, low 109,219 (28.8)
 Q2, middle 139,051 (36.6)
 Q3, high 131,595 (34.6)
Table 2 Number of  patients who were exposed to  statins 
and other lipid lowering agents
Data are based on time period between baseline and last health examination of 
each subject
a Bezafibrate, ciprofibrate, etofibrate, fenofibrate, and gemfibrozil
Medication Number (%) of patients 
who had exposure 
to medication
Cumulative duration 
(years) of exposure 
to medication
Any statin 96,182 (25.3) 165,083
 Atorvastatin 61,157 (16.1) 78,627
 Rosuvastatin 11,720 (3.1) 14,678
 Pitavastatin 8010 (2.1) 7691
 Pravastatin 8047 (2.1) 8099
 Simvastatin 46,773 (12.3) 46,768
 Lovastatin 9291 (2.4) 6045
 Fluvastatin 3786 (1.0) 3175
Fibratea 14,926 (3.9) 11,617
Ezetimibe 5847 (1.5) 5830
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but anDDD by pravastatin, lovastatin, and fluvastatin had 
non-significant positive effects. No statin type had sig-
nificant interaction effect with time interval in the linear 
mixed models.
Discussion
In this longitudinal study using the repeated measure-
ments of fasting glucose level in nationwide health exam-
inations, there was a statistically significant association 
between statin therapy and increase in fasting glucose 
in non-diabetic individuals (more adherent and inten-
sive statin users had higher fasting glucose). Non-statin 
lipid lowering medications of fibrate and ezetimibe were 
not associated with change in fasting glucose. When we 
analyzed individual statin types, all types of statins were 
positively associated with an increase in fasting glucose 
although the effects of pravastatin, lovastatin, and flu-
vastatin were not significant. Our findings are in line 
with the current consensus that statin can induce insu-
lin resistance, hyperglycemia, and new-onset DM [17, 
18]. However, our study should not be interpreted as 
to merely avoid statins due to the hyperglycemic effect. 
Overall evidence show that the benefits of statins far 
outweigh the potential hazards [19–21]. Statin therapy 
was associated with less good glycemic control in diabe-
tes and pre-diabetes, but there was a much lower risk of 
major cardiovascular events [22, 23]. Real-world studies 
consistently indicate that statins are frequently subopti-
mal and under prescribed in populations with high car-
diovascular risk [24–27].
When we plotted estimated change in fasting glu-
cose over time (Fig.  2), more adherent and intensive 
use of statins had positive effects on the change in fast-
ing glucose level, but there was no significant interac-
tion between statins and time interval. That means that 
use of statins may induce an increase in fasting glucose, 
Table 3 Results of the multivariate linear mixed models for the change in fasting glucose level
Data are derived from the linear mixed models for the change in fasting glucose (mmol/L). These variables were included as fixed-effect variables
PDC proportion of days covered by statins during the time period from baseline to serial health examination (ranged from 0 to 1, treated as a continuous variable)
a Value is the estimated change in fasting glucose when whole time period is covered by statins (PDC = 1)
b Bezafibrate, ciprofibrate, etofibrate, fenofibrate, and gemfibrozil
c When ‘anDDD by any statin’ were included in the multivariate linear mixed model instead of ‘PDC by any statin’
Coefficient (β) Standard error p
Variables at baseline
 Sex (male) 0.111 0.002 < 0.001
 Age (years) 0.003 < 0.001 < 0.001
 Baseline fasting glucose (mmol/L) − 0.764 0.001 < 0.001
Repeatedly measured variables at NHIS health examination
 Systolic blood pressure (per 10 mmHg) 0.028 < 0.001 < 0.001
 Body mass index (kg/m2) 0.023 < 0.001 < 0.001
 Current smoker 0.021 0.002 < 0.001
Alcohol consumption, frequency per week (times)
 < 1 Ref
 1–2 0.034 0.002 < 0.001
 3–4 0.094 0.002 < 0.001
 ≥ 5 0.116 0.003 < 0.001
Exercise, days per week (days)
 < 1 Ref
 1–4 − 0.005 0.001 < 0.001
 ≥ 5 − 0.011 0.002 < 0.001
Household income
 Q1, low Ref
 Q2, middle − 0.004 0.002 0.015
 Q3, high − 0.011 0.002 < 0.001
Time period from baseline to each health examination (year) 0.035 < 0.001 < 0.001
PDC by any  statina 0.093 0.007 < 0.001
PDC by  fibrateb 0.022 0.025 0.387
PDC by ezetimibe 0.046 0.045 0.314
anDDD by any  statinc 0.119 0.009 < 0.001
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but the slope of increase in fasting glucose over time 
was not associated with the statin therapy. Therefore, 
we supposed that there is no reason to avoid statins for 
high risk cardiovascular patients due to the concern for 
additional hyperglycemia over time induced by long-
term statin therapy. This finding was consistent with a 
prior meta-analysis evaluating the change in hemoglobin 
A1c (HbA1c) by statins in DM patients; there was no sig-
nificant interaction between the duration of statin treat-
ment and increase of HbA1c [28]. In addition, we found 
that the increase in fasting glucose was influenced by an 
unhealthy lifestyle of smoking, higher alcohol consump-
tion, and lower physical activity. Higher systolic blood 
pressure, higher BMI, and lower household income were 
also associated with increase in fasting glucose. These 
findings support the current recommendations highlight-
ing the importance of lifestyle modifications to prevent 
impaired glucose tolerance and DM [29].
With expanded indications for statin in the recent 
guidelines, statins have become the first-line therapy for 
cardiovascular protection [30]. As more patients take 
statins, there is awareness of unwanted side effects as 
well as benefits of statins [31]. Due to there are patho-
physiologic and epidemiologic data for a linkage between 
hyperglycemia and increased cardiovascular or all-cause 
mortality in diabetic and non-diabetic patients, phy-
sicians should be cautious about the potential risk of 
statin-mediated hyperglycemia and new-onset DM [32, 
33]. To maintain the cardiovascular benefit and mini-
malize the potentially adverse hyperglycemic effect with 
statins, multi-strategy approach should be considered, 
including monitoring of fasting glucose, control of pre-
disposing factors to glucose intolerance and unhealthy 
life-style, proper selection of the statin (type and dosage) 
and concomitant medications [21, 34]. Screening and risk 
stratification for diabetes on the initiation of statins and 
periodical monitoring of fasting glucose would be helpful 
for early diagnosis and proper glucose control in patients 
on statin therapy [33, 35]. Sustainable lifestyle changes 
can improve control of both glucose metabolism and 
cardiovascular risk [36]. Encouraging healthy dietary pat-
tern, physical activity, body weight control, and quitting 
smoking could be effective to prevent impaired glucose 
tolerance and DM [29, 37]. There are a number of medi-
cations with diabetogenic property such as thiazide diu-
retics and steroids; concomitant use of the medications 
may further increase the risk of impaired glucose metab-
olism and DM [38, 39].
To explain the diabetogenic effect of statins, numer-
ous mechanisms have been proposed. Glucose and lipid 
metabolism are interconnected in many ways [40]. Gene 
variants involved in lipid metabolism (Niemann-Pick 
C1-Like 1, Proprotein convertase subtilisin/kexin type 
9, and HMGCR) are significantly associated with obe-
sity, hyperglycemia and DM [41–43]. Lower prevalence 
of type 2 DM in patients with familial hypercholester-
olemia suggests genetic links between glucose and lipid 
metabolism [44]. Statins-induced cholesterol-dependent 
conformational changes in glucose transporter (GLUT) 
proteins can lead to impaired glucose uptake in the cells 
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Fig. 2 Effects of statin therapy on the change in fasting glucose over time. Plots illustrate the estimated change in fasting glucose (line) and 95% 
confidence interval (shadow) based on the multivariate linear mixed models adjusted for the variables listed in Table 3. a According to adherent use 
of statin therapy (PDC). b According to intensity of statin therapy (anDDD). PDC, proportion of days covered by statins for the time period between 
baseline and serial measurements of fasting glucose; anDDD, average number of defined daily doses per day for the time period between baseline 
and serial measurements of fasting glucose
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and insulin resistance [45]. Inhibition of de-novo choles-
terol synthesis by statins results in deleterious inflam-
mation and oxidation within islet β-cells, which lead to 
cellular apoptosis and impaired insulin secretion [46]. 
Biosynthesis of the isoprenoid side chain of coenzyme 
Q10 is suppressed by statins, which has been implicated 
in the downregulation of GLUT4 synthesis, mitochon-
drial oxidative stress, delayed adenosine triphosphate 
production, and apoptosis of β-cells, causing impaired 
glucose-stimulated insulin secretion [19, 47, 48]. Sim-
vastatin and atorvastatin have been shown to reduce 
the level of adiponectin, which is a hormone with anti-
inflammatory and anti-diabetogenic properties secreted 
by adipocytes [19, 49]. One of the most common com-
plaints with statins is muscle-related symptoms (muscle 
pain, myopathy, myalgia, and fatigue) [50]. Statin-related 
muscle complaints are frequently exacerbated by exer-
cise, which further limits physical activity and exercise 
performance [51]. Since physical inactivity is associated 
with abdominal adiposity, body weight gain, and glucose 
intolerance, limited physical activity by statins may be a 
mediator of glucose intolerance [23, 52, 53].
There are scarce data on the effects of individual statins 
on DM and diabetogenic potency. Previous meta-anal-
yses with randomized and observational studies have 
shown no clear difference between statin types in terms 
of DM incidence [5, 54]. The Women’s Health Initia-
tive showed that an increased risk of DM was observed 
for all types of statins [55]. Therefore, all statins seem to 
have a diabetogenic potency considered as a medication 
class effect [17]. However, individual statins have differ-
ent mechanisms of action and pharmacokinetic proper-
ties, and experimental data suggest that different statins 
have varying effects on glucose metabolism [56]. Based 
on available clinical and experimental data, it is generally 
accepted that atorvastatin, rosuvastatin, simvastatin, lov-
astatin, and fluvastatin have an unfavorable influence on 
glycemic parameters and risk of new-onset DM [57].
Some data suggested that pravastatin may have rela-
tively weak diabetogenicity compared to that of other 
Coefficient for PDC
Statin
atorvastatin
rosuvastatin
pitavastatin
pravastatin
simvastatin
lovastatin
fluvastatin
ß
0.108
0.069
0.080
0.026
0.118
0.044
0.021
95%CI
0.086;0.130
0.021;0.117
0.008;0.152
0.093;0.143
p
<0.001
0.005
0.030
0.318
<0.001
0.088
0.654
0 0.1 0.2 0.3 (mmol/L)
Coefficient for anDDD
Statin
atorvastatin
rosuvastatin
pitavastatin
pravastatin
simvastatin
lovastatin
fluvastatin
ß
0.154
0.061
0.088
0.049
0.162
0.108
0.040
95%CI
0.119;0.188
0.013;0.108
0.014;0.161
0.126;0.197
p
<0.001
0.012
0.020
0.148
<0.001
0.052
0.294
0 0.1 0.2 0.3 (mmol/L)
a
b
Fig. 3 Effects of individual statins on the change in fasting glucose. Data are coefficients (β) and 95% CIs of individual statins on the change in 
fasting glucose derived by the multivariate linear‑mixed models adjusted for the variables listed in Table 3. PDC, proportion of days covered by 
statins for the period between baseline and serial measurements of fasting glucose; anDDD, average number of defined daily doses per day; CI 
confidence interval
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statins [3]. In a network meta-analysis, pravastatin had 
the lowest risk of inducing new-onset DM among the 
high-dose statin therapy (atorvastatin 80  mg, rosuvas-
tatin 20 mg, simvastatin 40 mg, and pravastatin 40 mg), 
but the difference was not statistically significant [58]. 
The West of Scotland Coronary Prevention Study showed 
that pravastatin therapy resulted in a 30% reduction in 
the risk of new-onset DM compared to placebo [59]. 
The relatively lower risk of DM with pravastatin was 
also reported in retrospective studies using the real-
world data [60, 61]. Unlike other statins, pravastatin may 
increase plasma adiponectin levels and improve insulin 
sensitivity mediated by the elevation of calcitriol [62]. 
The hydrophilicity of pravastatin may have little effect on 
membrane-embedded proteins involving glucose metab-
olism such as the GLUT [63]. However, the Prospective 
Study of Pravastatin in the Elderly at Risk (PROSPER) 
trial showed that the risk of new-onset diabetes increased 
by 30% in patients treated with pravastatin compared 
with those given a placebo [64].
Pitavastatin is the newest statin and has been shown to 
be well-tolerated with fewer side effects and a relatively 
low drug interaction profile [65]. A recent meta-analysis 
of randomized controlled trials with pitavastatin sug-
gested that pitavastatin did not adversely affect glucose 
metabolism or increase risk of developing diabetes com-
pared to the controls [66]. In the Japan Prevention Trial 
of Diabetes by Pitavastatin in Patients With Impaired 
Glucose Tolerance (J-PREDICT) trial, treatment with 
pitavastatin reduced the risk of new‐onset DM by 18% 
in patients with impaired glucose tolerance [67]. The 
Japanese long-term prospective post-marketing surveil-
lance LIVALO Effectiveness and Safety (LIVES) study 
demonstrated that treatment with pitavastatin lowered 
HbA1c (from 8.1% at baseline to 7.4% at 6 months) in the 
patients with poorly controlled diabetes [68].
In our study, all classes of statins were associated with 
an increase in fasting glucose although the effects of 
pravastatin, lovastatin, and fluvastatin were not signifi-
cant. In our data, the hyperglycemic effects of pitavasta-
tin does not seem to be lower than that of other statins in 
contrast to the favorable reports for pitavastatin on glu-
cose metabolism. A recent retrospective cohort study in 
Korea also reported that pitavastatin had the highest risk 
of new-onset DM compared to other statins [69].
In a number of prior studies, there are inconsistent 
findings about the diabetogenic property of individual 
statins. The discrepancy could be originated from dif-
ference in baseline characteristics of study population, 
coexisting risk factors, follow-up duration, medication 
adherence and so on. It is known that statin-induced DM 
risk is higher in pre-diabetes and patients with predispos-
ing factors for DM such as old age and obesity [34]. The 
short-term and long-term effects on glucose metabolism 
may be different in accordance with type of statins and 
underlying characteristics of patients [70]. The diabe-
togenic effect of statins may be varied in genetic back-
ground [71]. In patients who were prescribed statins, 
discontinuation and poor adherence were common in 
clinical practice, which limits assessing the diabetogenic 
effect of statins [72]. The effect of statins on glucose 
metabolism are complex and interconnected by multi-
ple pathways; individual statins may have a heterogenous 
impact on the multiple processes [11]. To obtain further 
knowledge of individual statins on glucose metabolism, 
there is need for further extensive studies.
This study had both strengths and limitations. From a 
population-based nationwide health screening program, 
we collected data from a large cohort of 379,865 patients 
over a 10-year study period. Serial data of more than 
2,000,000 measurements of fasting glucose were ana-
lyzed. Besides data on fasting glucose, we also included 
detailed data on blood pressure, BMI, and lifestyle. The 
significant effects of an unhealthy lifestyle on fasting glu-
cose including smoking, higher alcohol intake, higher 
BMI and lower physical activity may support the rele-
vance of this study. In Korea, statins must be prescribed 
by physicians and refill programs at pharmacies are not 
allowed. Using the health insurance claim data, pre-
scription records for individual statin could be accessed. 
However, the actual intake of statins in subjects might 
be different from the prescription records. Fortunately, 
there was good correlation between prescription and 
real exposure to drugs in prior studies [73, 74]. Our study 
was retrospectively performed and due to the observa-
tional nature, there was a possibility of hidden bias due to 
uncollected data. We excluded a large proportion of sub-
jects with DM or who had received anti-diabetic medi-
cation during the study period to eliminate the potential 
bias caused by the effects of this medication on glucose 
level. The item for physical activity lacked data for the 
type and duration of exercise. This study was based on 
Koreans; the response to statins might be varied in other 
genetic population. Therefore, our results should be 
interpreted with caution and further studies are needed 
to confirm these findings in other populations.
Conclusions
There was significant increase of fasting glucose in 
non-diabetic individuals in proportion to adherent and 
intensive use of statins. Among the statin subtypes, use 
of atorvastatin, rosuvastatin, pitavastatin and simvas-
tatin were associated with significant increase in fast-
ing glucose. Pravastatin, lovastatin, and fluvastatin also 
had trend toward an increased fasting glucose, but were 
statistically non-significant. These finding suggested 
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medication class effect of all types of statins predispos-
ing hyperglycemia although there was some difference 
in the degree according to the type. We need to find 
optimal strategy to maximize the cardiovascular benefit 
and minimalize the hyperglycemic effect by statins.
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